

Person Closely Associated Dealing

Oxford, UK - 27 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that Pippa Radcliffe, a person closely associated with Kyriacos Mitrophanous, Chief Innovation Officer of the Company, exercised 839 options at nil cost and disposed 274 shares at £3 per share on 25 June 2024.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.	Details of the Person Closely Associated ("PCA")						
a)	Name	Pippa Radcliffe					
2.	Reason for the notification						
a)	Position/status	This notification concerns Pippa Radcliffe in her capacity as a person closely associated with a person discharging managerial responsibilities. The person discharging managerial responsibilities is Kyriacos Mitrophanous, Chief Innovation Officer of the Company. The association arises by virtue of Pippa Radcliffe being the spouse of Kyriacos Mitrophanous.					
b)	Initial notification/ amendment	Initial Notification/Amendment					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares of 50 pence each					
	Identification code	ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Exercise of Options at nil cost					
c)	Currency	GBP - British pound					
d)	Price(s) and volumes(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>Nil</td><td>839</td></tr></table>		Price(s)	Volume(s)	Nil	839
Price(s)	Volume(s)						
Nil	839						
e)	Aggregated information <ul style="list-style-type: none">- Aggregate volume- Price- Aggregated total	839 NIL NIL					
f)	Date of the transaction	2024-06-25					
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Pippa Radcliffe	
2.	Reason for the notification		
a)	Position/status	This notification concerns Pippa Radcliffe in her capacity as a person closely associated with a person discharging managerial responsibilities. The person discharging managerial responsibilities is Kyriacos Mitrophanous, Chief Innovation Officer of the Company. The association arises by virtue of Pippa Radcliffe being the spouse of Kyriacos Mitrophanous.	
b)	Initial notification/ amendment	Initial Notification	

2)	Initial notification amendment	Initial notification				
3.	Details of the Issuer					
a)	Name	Oxford BioMedica plc				
b)	LEI code	213800S1GVQNXQ15K851				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43				
b)	Nature of the transaction	Disposal				
c)	Currency	GBP - British pound				
d)	Price(s) and volumes(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£3</td><td>274</td></tr></table>	Price(s)	Volume(s)	£3	274
Price(s)	Volume(s)					
£3	274					
e)	Aggregated information - Aggregate volume - Price - Aggregated total	274 £3 £822.00				
f)	Date of the transaction	2024-06-25				
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)				

-Ends-

For further information, please contact:

Oxford Biomedica plc:
Natalie Walter, Company Secretary

Tel: +44 (0)1865 783 000

ABOUT OXFORD BIOMEDICA

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on [LinkedIn](#) and [YouTube](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFEFRVIDFIS